Publication | Closed Access

Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody

Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseSuccessful TreatmentMedicineHematologyImmunologyAutoimmunityHuman Anti-chimeric AntibodyAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation OncologyHealth Sciences